REGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.72B

-1.74%

10.705

-11.31%

3.42B

+12.81%

10.479

+27.48%

3.68B

+0.02%

11.668

-9.48%

Estimates Revision

The market is revising Upward the revenue expectations for Regeneron Pharmaceuticals, Inc. (REGN) for FY2025, with the revenue forecasts being adjusted by 2.28% over the past three months. During the same period, the stock price has changed by 42.06%.

Revenue Estimates for FY2025

Revise Upward

+2.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+9.13%

In Past 3 Month

Stock Price

Go Up

+42.06%

In Past 3 Month

22 Analyst Rating

Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 742.00 USD with a low forecast of 627.00 USD and a high forecast of 870.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

5 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

627.00

Averages

742.00

High

870.00

Current: 0.000

Low

627.00

Averages

742.00

High

870.00

BofA

Underperform

Buy

upgrade

$627 -> $860

2026-01-07

New

Reason

BofA

Price Target

$627 -> $860

2026-01-07

New

upgrade

Underperform

Buy

Reason

BofA upgraded Regeneron to Buy from Underperform with a price target of $860, up from $627.

BofA

Underperform

Buy

upgrade

$627 -> $860

2026-01-07

New

Reason

BofA

Price Target

$627 -> $860

2026-01-07

New

upgrade

Underperform

Buy

Reason

As previously reported, BofA double upgraded Regeneron to Buy from Underperform with a price target of $860, up from $627. The firm's more bullish view is driven by multiple factors, including the fact that its prior Underperform thesis around Eylea SD has played out as consensus estimates have come down. In addition, the firm is more bullish on Eylea HD's potential in light of multiple label updates and its estimates are now "meaningfully higher" than consensus, the analyst tells investors. The firm also sees potential for further upside from Dupixent and potential upside from the pipeline in 2026.

Citi

Buy

upgrade

$700 -> $900

2026-01-07

New

Reason

Citi

Price Target

$700 -> $900

2026-01-07

New

upgrade

Buy

Reason

Citi raised the firm's price target on Regeneron to $900 from $700 and keeps a Buy rating on the shares.

Morgan Stanley

Terence Flynn

Equal Weight

maintain

$767 -> $768

2025-12-12

Reason

Morgan Stanley

Terence Flynn

Price Target

$767 -> $768

2025-12-12

maintain

Equal Weight

Reason

Morgan Stanley analyst Terence Flynn raised the firm's price target on Regeneron to $768 from $767 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Buy

maintain

$890 -> $985

2025-12-10

Reason

HSBC

Price Target

$890 -> $985

2025-12-10

maintain

Buy

Reason

HSBC raised the firm's price target on Regeneron to $985 from $890 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

BMO Capital

Evan Seigerman

Outperform

maintain

$725 -> $850

2025-12-04

Reason

BMO Capital

Evan Seigerman

Price Target

$725 -> $850

2025-12-04

maintain

Outperform

Reason

BMO Capital analyst Evan Seigerman raised the firm's price target on Regeneron to $850 from $725 and keeps an Outperform rating on the shares. Following Regeneron's itepekimab miss in June, shares have appreciated about 50% as efforts to resolve regulatory uncertainty have started to pay dividends, the analyst tells investors in a research note. BMO adds it is raising its target price as the firm expects higher contributions from Dupixent and more moderate erosion of 2mg Eylea than previously estimated.

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 17.21, compared to its 5-year average forward P/E of 16.15. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

16.15

Current PE

17.21

Overvalued PE

20.06

Undervalued PE

12.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.09

Current EV/EBITDA

10.56

Overvalued EV/EBITDA

14.15

Undervalued EV/EBITDA

8.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.69

Current PS

5.37

Overvalued PS

6.91

Undervalued PS

4.46

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 167% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

REGN News & Events

Events Timeline

No data

News

8.5

01-07Globenewswire

PinnedRegeneron Science Talent Search 2026 Announces 300 Scholars

9.0

15:03 PMBenzinga

Immuneering Updates Pancreatic Cancer Trial Data, Survival Rates Show Significant Improvement

4.5

00:04 AMNASDAQ.COM

US Stock Market Volatile, Nasdaq Hits 3.5-Week High

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

The current price of REGN is 801.01 USD — it has decreased -1.39 % in the last trading day.

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

What is the price predicton of REGN Stock?

What is Regeneron Pharmaceuticals Inc (REGN)'s revenue for the last quarter?

Regeneron Pharmaceuticals Inc revenue for the last quarter amounts to 3.75B USD, increased 0.90 % YoY.

What is Regeneron Pharmaceuticals Inc (REGN)'s earnings per share (EPS) for the last quarter?

Regeneron Pharmaceuticals Inc. EPS for the last quarter amounts to 13.62 USD, increased 18.02 % YoY.

What changes have occurred in the market's expectations for Regeneron Pharmaceuticals Inc (REGN)'s fundamentals?

How many employees does Regeneron Pharmaceuticals Inc (REGN). have?

Regeneron Pharmaceuticals Inc (REGN) has 15106 emplpoyees as of January 08 2026.

What is Regeneron Pharmaceuticals Inc (REGN) market cap?

Today REGN has the market capitalization of 85.37B USD.